Drug intelligence / Profile preview

BOX101-1

Development stage: Unknown
Lead developer: Bostal Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

BOX101-1 is a long-acting injectable (LAI) formulation of semaglutide developed by Bostal Pharma for the treatment of type 2 diabetes mellitus and obesity. Designed for once-monthly (1M) subcutaneous administration, BOX101-1 utilizes Bostal's proprietary drug delivery technologies (such as microsphere-based or in-situ gel-forming depot systems) to provide stable and extended release of semaglutide. As a glucagon-like peptide-1 (GLP-1) receptor agonist, it mimics the action of endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon secretion, and slow gastric emptying, thereby improving glycemic control and promoting weight loss. BOX101-1 is currently in Phase 2/3 clinical development.

Other names: Semaglutide LAISemaglutide LAI, 1Msemaglutide long-acting injectable

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on BOX101-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOX101-1.

Explore the full profile